Spots Global Cancer Trial Database for Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
Official Title: A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
Study ID: NCT03927573
Interventions
Study Description
Brief Summary: This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM3PSCA in patients with prostate stem cell antigen (PSCA) expressing cancer types which failed to respond to standard therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum rechts der Isar der TU München, Munich, Bayern, Germany
Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Universitätsklinikum Marburg, Marburg, Hessen, Germany
Universitätsklinikum Dresden, Dresden, Sachsen, Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, , Germany
Contact Details
Name: Ralf Bargou, Prof. Dr.
Affiliation: Universitätsklinikum Würzburg, Interdisziplinäres Studienzentrum mit ECTU
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
